UPDATE: MLV & Co Raises PT On Halozyme Therapeutics On Promising Start To 2015

By: via Benzinga
In a report published Thursday, MLV & Co analyst Arlinda Lee reiterated a Buy rating on Halozyme Therapeutics (NASDAQ: HALO), and raised ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.